MedPath

PregLem SA

PregLem SA logo
🇨🇭Switzerland
Ownership
Private, Subsidiary
Established
2006-01-01
Employees
11
Market Cap
-
Website
http://www.preglem.com

Clinical Trials

12

Active:2
Completed:8

Trial Phases

2 Phases

Phase 2:2
Phase 3:6

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 3
6 (75.0%)
Phase 2
2 (25.0%)

Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting

Conditions
Uterine Fibroids
First Posted Date
2016-04-22
Last Posted Date
2019-10-16
Lead Sponsor
PregLem SA
Target Recruit Count
1500
Registration Number
NCT02748460
Locations
🇧🇪

Cliniques Universitaires Saint-Luc, Bruxelles, Belgium

🇧🇪

Universitair Ziekenhuis Gent, Gent, Belgium

🇧🇪

Centre Hospitalier Regional De La Citadelle, Liege, Belgium

and more 102 locations

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata

Phase 3
Completed
Conditions
Uterine Fibroids
Interventions
First Posted Date
2012-07-17
Last Posted Date
2016-01-08
Lead Sponsor
PregLem SA
Target Recruit Count
64
Registration Number
NCT01642472
Locations
🇦🇹

Medical University Vienna, Vienna, Austria

🇧🇪

Cliniques Universitaires Saint-Luc, Gynécologie-Obstétrique,, Brussels, Belgium

🇧🇪

CHR de la Citadelle, Liège, Belgium

and more 13 locations

A Prospective Multicenter Non-interventional Study of Women Treated With ESMYA (Ulipristal Acetate) as Pre-operative Treatment of Moderate to Severe Symptoms of Uterine Fibroids

Conditions
Uterine Fibroids
First Posted Date
2012-07-09
Last Posted Date
2015-01-27
Lead Sponsor
PregLem SA
Target Recruit Count
1500
Registration Number
NCT01635452
Locations
🇦🇹

LKH Klagenfurt, Klagenfurt, Austria

🇵🇱

Private practice, Lublin, Poland

🇫🇷

CHU Pellegrin Gynécologie, Bordeaux, France

and more 58 locations

PGL2001 Proof of Concept Study in Symptomatic Endometriosis

Phase 2
Completed
Conditions
Endometriosis
Interventions
Drug: PGL2001 + Primolut-Nor 5
Drug: Placebo + Primolut-Nor 5
First Posted Date
2012-06-29
Last Posted Date
2014-06-03
Lead Sponsor
PregLem SA
Target Recruit Count
162
Registration Number
NCT01631981
Locations
🇭🇺

Synexus Magyarország Kft., Budapest, Hungary

🇭🇺

Semmelweis Egyetem II. Szülészeti és Nőgyógyászati Klinika, Budapest, Hungary

🇭🇺

Debreceni Egyetem Orvos-es Egeszsegtudomanyi Centrum Szuleszeti es Nogyogyaszati Klinika, Debrecen, Hungary

and more 17 locations

PGL5001 Proof of Concept Study in Inflammatory Endometriosis

Phase 2
Completed
Conditions
Endometriosis
Interventions
Drug: Placebo
First Posted Date
2012-06-28
Last Posted Date
2014-06-03
Lead Sponsor
PregLem SA
Target Recruit Count
24
Registration Number
NCT01630252
Locations
🇵🇱

Prywatna Klinika Połozniczo-Ginekologiczna Sp z o.o., Bialystok, Poland

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.